Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group

European Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2011, Pages 5387-5397

  Zhang, Yingjie ^a   Feng, Jinhong ^a   Jia, Yuping ^a   Xu, Yingying ^a   Liu, Chunxi ^a   Fang, Hao ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

1,4 Dithia 7 azaspiro 4,4 nonane 8 carboxylic acid derivatives; Histone deacetylases; Inhibitor; Synthesis

Indexed keywords

6 [7 (2 (TERT BUTOXYCARBONYLAMINO)ACETYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOIC ACID; 6 [7 (2 (TERT BUTOXYCARBONYLAMINO)BUTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOIC ACID; 6 [7 (3 (TERT BUTOXYCARBONYLAMINO)PROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOIC ACID; 6 [7 (4 (TERT BUTOXYCARBONYLAMINO)BUTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOIC ACID; 7 (TERT BUTOXYCARBONYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXYLIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; METHYL 6 (1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO)HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 (1H INDOL 3 YL)PROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 (4 HYDROXYPHENYL)PROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 HYDROXYPROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 METHYLBUTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 METHYLPENTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 3 PHENYLPROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO) 4 METHYLPENTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO)ACETYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO)HEXANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (2 (TERT BUTOXYCARBONYLAMINO)PROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (3 (TERT BUTOXYCARBONYLAMINO)PROPANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 [7 (4 (TERT BUTOXYCARBONYLAMINO)BUTANOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDO]HEXANOATE; METHYL 6 AMINOHEXANOATE HYDROCHLORIDE; N(6 (HYDROXYAMINO) 6 OXOHEXYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 8 CARBOXAMIDE HYDROCHLORIDE; TERT BUTYL 1 [8 (6 (HYDROXYAMINO) 6 OXOHEXYLCARBAMOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONAN 7 YL] 1 OXO 3 PHENYLPROPAN 2 YLCARBAMATE; TERT BUTYL 1E[8 (6 (HYDROXYAMINO) 6 OXOHEXYLCARBAMOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONAN 7 YL] 3 (4 HYDROXYPHENYL) 1 OXOPROPAN 2 YLCARBAMATE; TERT BUTYL 2 [8 (6 METHOXY 6 OXOHEXYLCARBAMOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 7 CARBONYL]PYRROLIDINE 1 CARBOXYLATE; TERT BUTYL 4 [8 (6 METHOXY 6 OXOHEXYLCARBAMOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 7 CARBONYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 8 (6 METHOXY 6 OXOHEXYLCARBAMOYL) 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 7 CARBOXYLATE; TERT BUTYL 8 [6 (HYDROXYAMINO) 6 OXOHEXYLCARBAMOYL] 1,4 DITHIA 7 AZASPIRO[4.4]NONANE 7 CARBOXYLATE; TRIPEPTIDOMIMETIC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

AMINO ACIDS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; PEPTIDOMIMETICS;

EID: 80054921479     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.08.045     Document Type: Article

References (37)

1. C.A. Hassig, and S.L. Schreiber Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs Curr. Opin. Chem. Biol. 1 1997 300 308 (Pubitemid 127437155)
2. T. Kouzarides Histone acetylases and deacetylases in cell proliferation Curr. Opin. Genet. Dev. 9 1999 40 48 (Pubitemid 29080385)
3. A.P. Wolffe Histone deacetylase: a regulator of transcription Science 272 1996 371 372 (Pubitemid 26138173)
4. M. Dokmanovic, C. Clarke, and P.A. Marks Histone deacetylase inhibitors: overview and perspectives Mol. Cancer Res. 5 2007 981 989 (Pubitemid 350080267)
5. S. Ropero, and M. Esteller The role of histone deacetylases (HDACs) in human cancer Mol. Oncol. 1 2007 19 25 (Pubitemid 46776612)
6. A.J. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B. van Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 370 2003 737 749 (Pubitemid 36399066)
7. M.A. Glozak, N. Sengupta, X.H. Zhang, and E. Seto Acetylation and deacetylation of non-histone proteins Gene 363 2005 15 23 (Pubitemid 41691888)
8. K. Halkidou, L. Gaughan, S. Cook, H.Y. Leung, D.E. Neal, and C.N. Robson Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer Prostate 59 2004 177 189 (Pubitemid 38481229)
9. J.H. Choi, H.J. Kwon, B.I. Yoon, J.H. Kim, S.U. Han, H.J. Joo, and D.Y. Kim Expression profile of histone deacetylase 1 in gastric cancer tissues Jpn. J. Cancer Res. 92 2001 1300 1304 (Pubitemid 34036893)
10. A.J. Wilson, D.S. Byun, N. Popova, L.B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L.H. Augenlicht, and J.M. Mariadason Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J. Biol. Chem. 281 2006 13548 13558 (Pubitemid 43855268)
11. Z.H. Zhang, H. Yamashita, T. Toyama, H. Sugiura, Y. Ando, K. Mita, M. Hamaguchi, Y. Hara, S. Kobayashi, and H. Iwase Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast Breast Cancer Res. Treat. 94 2005 11 16 (Pubitemid 41416937)
12. P. Zhu, E. Martin, J. Mengwasser, P. Schlag, K.P. Janssen, and M. Gottlicher Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis Cancer Cell. 5 2004 455 463 (Pubitemid 38610247)
13. B.H. Huang, M. Laban, C.H. Leung, L. Lee, C.K. Lee, M. Salto-Tellez, G.C. Raju, and S.C. Hooi Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 Cell Death Differ. 12 2005 395 404 (Pubitemid 40520691)
14. J. Song, J.H. Noh, J.H. Lee, J.W. Eun, Y.M. Ahn, S.Y. Kim, S.H. Lee, W.S. Park, N.J. Yoo, J.Y. Lee, and S.W. Nam Increased expression of histone deacetylase 2 is found in human gastric cancer APMIS 113 2005 264 268 (Pubitemid 40676807)
15. Z.H. Zhang, H. Yamashita, T. Toyama, H. Sugiura, Y. Omoto, Y. Ando, K. Mita, M. Hamaguchi, S.I. Hayashi, and H. Iwase HDAC6 expression is correlated with better survival in breast cancer Clin. Cancer Res. 10 2004 6962 6968 (Pubitemid 39383047)
16. A. Al-Janadi, S.R. Chandana, and B.A. Cloney Histone deacetylation: an attractive target for cancer therapy? Drugs R&D 9 2008 369 383
17. L.M. Butler, D.B. Agus, H.I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H.T. Thaler, R.A. Rifkind, P.A. Marks, and V.M. Richon Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res. 60 2000 5165 5170
18. K. Garber Nat. Biotechnol. HDAC Inhibitors Overcome First Hurdle 25 2007 17 19
19. S. Grant, C. Easley, P. Kirkpatrick, and Vorinostat Nat. Rev. Drug Discov. 6 2007 21 22
20. P.A. Marks, and R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 25 2007 84 90 (Pubitemid 46087907)
21. C. Campas-Moya Romidepsin for the treatment of cutaneous T-cell lymphoma Drugs Today (Barc) 45 2009 787 795
22. Y. Zhang, H. Fang, J. Jiao, and W. Xu The structure and function of histone deacetylases: the target for anti-cancer therapy Curr. Med. Chem. 15 2008 2840 2849
23. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, R. Breslow, and N.P. Pavletich Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193 (Pubitemid 29436325)
24. Y. Zhang, J. Feng, C. Liu, L. Zhang, J. Jiao, H. Fang, L. Su, X. Zhang, J. Zhang, M. Li, B. Wang, and W. Xu Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors Bioorg. Med. Chem. 18 2010 1761 1772
25. Y. Zhang, J. Feng, Y. Jia, X. Wang, L. Zhang, C. Liu, H. Fang, and W. Xu Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities J. Med. Chem. 54 2011 2823 2838
26. Y. Zhang, J. Feng, C. Liu, H. Fang, and W. Xu Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors Bioorg. Med. Chem. 19 2011 4437 4444
27. T.A. Miller, D.J. Witter, and S. Belvedere Histone deacetylase inhibitors J. Med. Chem. 46 2003 5097 5116 (Pubitemid 37414179)
28. M. Paris, M. Porcelloni, M. Binaschi, and D. Fattori Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 21 2008 1505 1529 (Pubitemid 351438836)
29. O. Witt, H.E. Deubzer, T. Milde, and I. Oehme HDAC family: what are the cancer relevant targets? Cancer Lett. 277 2009 8 21
30. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 22 2008 1026 1034 (Pubitemid 351689885)
31. K. KrennHrubec, B.L. Marshall, M. Hedglin, E. Verdin, and S.M. Ulrich Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors Bioorg. Med. Chem. Lett. 17 2007 2874 2878 (Pubitemid 46636249)
32. E. Hu, E. Dul, C. Sung, Z. Chen, R. Kirkpatrick, G. Zhang, K. Johanson, R. Liu, A. Lago, G. Hofmann, R. Macarron, M. De los Frailes, P. Perez, J. Krawiec, J. Winkler, and M. Jaye Identification of novel isoform-selective inhibitors within class I histone deacetylases J. Pharmacol. Exp. Ther. 307 2003 720 728 (Pubitemid 37310689)
33. B. He, S. Velaparthi, G. Pieffet, C. Pennington, A. Mahesh, D.L. Holzie, M. Brunsteiner, R. von Breemen, S.Y. Blond, and P.A. Petukhov Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors J. Med. Chem. 52 2009 7003 7013
34. R. Neelarapu, D.L. Holzie, S. Velaparthi, H. Bai, M. Brunsteiner, S.Y. Blond, and P.A. Petukhov Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes J. Med. Chem. 54 2011 4350 4364
35. G. Estiu, N. West, R. Mazitschek, E. Greenberg, J.E. Bradner, and O. Wiest On the inhibition of histone deacetylase 8 Bioorg. Med. Chem. 18 2010 4103 4110
36. J.R. Somoza, R.J. Skene, B.A. Katz, C. Mol, J.D. Ho, A.J. Jennings, C. Luong, A. Arvai, J.J. Buggy, E. Chi, J. Tang, B.C. Sang, E. Verner, R. Wynands, E.M. Leahy, D.R. Dougan, G. Snell, M. Navre, M.W. Knuth, R.V. Swanson, D.E. McRee, and L.W. Tari Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases Structure 12 2004 1325 1334 (Pubitemid 38900774)
37. F. Gigante, M. Kaiser, R. Brun, and I.H. Gilbert SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents Bioorg. Med. Chem. 17 2009 5950 5961